Otsuka Launches Early Access Program for Investigational FUS-ALS Therapy Ulefnersen
Event summary
- Otsuka has initiated a global early access program (EAP) for ulefnersen, an investigational RNA-targeted therapy for FUS-ALS, a rare and rapidly progressive form of ALS.
- The EAP is available to eligible patients with a confirmed genetic diagnosis of FUS-ALS who cannot participate in ongoing clinical trials.
- Ulefnersen has received Fast Track designation from the FDA and Orphan Drug designation from the FDA, EMA, and Swissmedic.
- Otsuka licensed ulefnersen from Ionis Pharmaceuticals in 2024 under an exclusive global agreement.
The big picture
Otsuka's move to establish an EAP for ulefnersen underscores the critical unmet need for treatments in FUS-ALS, a rapidly progressive and often fatal neurodegenerative disease. The program reflects a strategic shift toward patient-centric access models, particularly for rare genetic disorders where clinical trial participation may be limited. The broader industry trend of leveraging early access programs to gather real-world evidence while advancing regulatory approvals could set a precedent for other orphan drug developers.
What we're watching
- Regulatory Pathway
- Whether ulefnersen can secure full regulatory approval given its investigational status and the lack of current therapies for FUS-ALS.
- Clinical Efficacy
- The pace at which clinical evidence accumulates to support ulefnersen's long-term viability as a FUS-ALS treatment.
- Market Positioning
- How Otsuka positions ulefnersen in a competitive landscape where other RNA-targeted therapies may emerge for ALS subtypes.